Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Overindulgence TFM Gets Bloated With Belching, Gas Indications

This article was originally published in The Tan Sheet

Executive Summary

FDA will allow for the inclusion of two new indications for bismuth subsalicylate products, according to a proposed amendment to the overindulgence Tentative Final Monograph in the Jan. 5 Federal Register

You may also be interested in...



Unified agenda

FDA will announce a Notice of Proposed Rulemaking in June on "the use of stimulant active ingredients to relieve symptoms associated with a hangover" in OTC products, the agency announces in HHS' semi-annual "unified agenda." The document, which was published in the Federal Register April 24, also notes that final action is slated for December on a proposal to require additional warnings for OTC bronchodilators containing ephedrine or epinephrine. The proposed amendment was issued by FDA in July (1"The Tan Sheet" July 18, 2005, p. 10). FDA also expects to take final action in August on a proposed rule to allow new indications for bismuth subsalicylate products. The proposal was announced in January 2005 (2"The Tan Sheet" Jan. 10, 2005, p. 7)...

Unified agenda

FDA will announce a Notice of Proposed Rulemaking in June on "the use of stimulant active ingredients to relieve symptoms associated with a hangover" in OTC products, the agency announces in HHS' semi-annual "unified agenda." The document, which was published in the Federal Register April 24, also notes that final action is slated for December on a proposal to require additional warnings for OTC bronchodilators containing ephedrine or epinephrine. The proposed amendment was issued by FDA in July (1"The Tan Sheet" July 18, 2005, p. 10). FDA also expects to take final action in August on a proposed rule to allow new indications for bismuth subsalicylate products. The proposal was announced in January 2005 (2"The Tan Sheet" Jan. 10, 2005, p. 7)...

Unified agenda

FDA will announce a Notice of Proposed Rulemaking in June on "the use of stimulant active ingredients to relieve symptoms associated with a hangover" in OTC products, the agency announces in HHS' semi-annual "unified agenda." The document, which was published in the Federal Register April 24, also notes that final action is slated for December on a proposal to require additional warnings for OTC bronchodilators containing ephedrine or epinephrine. The proposed amendment was issued by FDA in July (1"The Tan Sheet" July 18, 2005, p. 10). FDA also expects to take final action in August on a proposed rule to allow new indications for bismuth subsalicylate products. The proposal was announced in January 2005 (2"The Tan Sheet" Jan. 10, 2005, p. 7)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel